Pharmacophore an International Research Journal
Background: The specific action of sclerostin, is as an antagonistic ligand, for the Wnt LRP5/6 co-receptors. The current study aimed to estimate the circulating sclerostin levels as coronary heart disease novel biomarker in Iraqi individuals with type 2 diabetes (T2DM). The present study included 300 types 2 diabetic patients; 150 of them had coronary heart diseases (T2DM-CHD), and the remaining 150 diabetic patients (T2DM) served as a pathological control group. Receiver operating characteristics (ROC) curve analysis was used to determine the usefulness of sclerostin and BNP as markers for coronary heart disease in T2DM patients. Serum sclerostin level in T2DM-CHD was significantly higher when compared with the T2DM group (181.357±10.959 versus 154.285±12.377 P<0.0001). Also, serum BNP level was significantly higher in T2DM-CHD compared with age-gender match T2DM patients (230.456±92.588 versus 162.317±57.528 P<0.0001). The concentration of serum sclerostin >163.636pg/ml showed a sensitivity of 94% and specificity of 99% to identify coronary heart disease risk in T2DM patients. While the concentration of serum BNP >199.327pg/ml showed a sensitivity of 61.2% and specificity of 99.8% to identify the risk of CHD in T2DM patients. The data highlighted the fact that serum sclerostin may be a better biomarker than BNP in T2DM-CHD subjects.
